VMTHF (Venus Medtech (Hangzhou)) Growth Rank: 6 (As of Aug. 04, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VMTHF Venus Medtech (Hangzhou) Inc VMTHF
52 GF Score
Price $0.42
GF Value $1.27
! 4 Warning Signs
View Full Analysis

What is Venus Medtech (Hangzhou) Growth Rank?

Venus Medtech (Hangzhou) VMTHF 52 Growth Rank is 6 as of Aug. 04, 2026, which is at its 10-year median of 6.00. GuruFocus rates VMTHF with a GF Score™ of 52/100 and a GF Value™ of $1.27. The stock has 4 warning signs investors should review.

Venus Medtech (Hangzhou) has the Growth Rank of 6.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Venus Medtech (Hangzhou) Growth Rank Related Terms

VMTHF vs ABT, SYK, MDT: Growth Rank Comparison

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Venus Medtech (Hangzhou) Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Growth Rank distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s Growth Rank falls into.


VMTHF
52GF Score
Venus Medtech (Hangzhou) Inc VMTHF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 6 mean?
Venus Medtech (Hangzhou) (VMTHF) has a Growth Rank of 6 as of Aug. 04, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Venus Medtech (Hangzhou) and its competitors. This is near median its historical median of 6.00. Over the past decade, Venus Medtech (Hangzhou)'s Growth Rank has ranged from 2.00 to 10.00.
Is Venus Medtech (Hangzhou)'s Growth Rank too high?
Venus Medtech (Hangzhou)'s current Growth Rank of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Growth Rank compare to ABT and SYK?
Venus Medtech (Hangzhou)'s Growth Rank of 6 can be compared against companies in the Medical Devices & Instruments industry. Historically, Venus Medtech (Hangzhou)'s own Growth Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Venus Medtech (Hangzhou) and its competitors. Venus Medtech (Hangzhou)'s current Growth Rank is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Venus Medtech (Hangzhou) (VMTHF) has a current Growth Rank of 6. The stock's GF Value™ is $1.27, compared to a current price of $0.42 — trading 66.8% below its estimated fair value. The current Growth Rank is 6, which is near median its 10-year median of 6.00. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (VMTHF), the current Growth Rank is 6 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued. The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.

Key valuation signals for VMTHF:

  • Growth Rank: 6 (near median its 10-year median of 6.00)
  • GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Venus Medtech (Hangzhou) Business Description

Other Exchanges 02500:Hong Kong
Address No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score

Get the complete analysis for VMTHF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price
$1.27
GF Value